RN
Raghunandan Nilkanthrao Kadam
About Raghunandan Nilkanthrao Kadam
Data last updated:
Raghunandan Nilkanthrao Kadam has 8 years in corporate governance. Holds Director role. Currently with 1 company, including Strimed Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Strimed Pharmaceuticals Private Limited at ₹1.47 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 24 Feb 2018 | 2018 | ₹1.47 Cr (FY 2025) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Raghunandan Nilkanthrao Kadam
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Raghunandan Nilkanthrao Kadam
Raghunandan Nilkanthrao Kadam has 8 years in corporate governance. Holds Director role. Currently with 1 company, including Strimed Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Strimed Pharmaceuticals Private Limited at ₹1.47 Cr (FY 2025).
Raghunandan Nilkanthrao Kadam is associated with 1 company as Director, including Strimed Pharmaceuticals Private Limited (₹1.47 Cr).
Raghunandan Nilkanthrao Kadam has expertise in General Business.
Raghunandan Nilkanthrao Kadam has 8 years in corporate governance.
By reported revenue, the largest current company of Raghunandan Nilkanthrao Kadam is Strimed Pharmaceuticals Private Limited, with revenue of ₹1.47 Cr (FY 2025).
Raghunandan Nilkanthrao Kadam currently holds positions at 1 company: Strimed Pharmaceuticals Private Limited (₹1.47 Cr).